Abstract
The drug tenofovir is central to the daily drug regimens that keep HIV-positive individuals healthy and that protect those at risk of infection. But at least 30% of those prescribed the medication don’t take it consistently, which contributes to viral resistance. A new test is a first step toward a low-cost, point-of-care lab diagnostic that monitors treatment compliance over the previous several weeks (ACS Sensors 2020, DOI: 10.1021/acssensors.9b02198). Because tenofovir lasts in blood and urine for just a few days, analyzing those samples doesn’t show whether a person has been taking the drug regularly. So researchers looked instead to tenofovir diphosphate, the drug’s active form, because it remains in the blood for several weeks and is a better indicator of compliance. The team added viral genetic templates and a DNA-binding fluorescent dye to blood samples spiked with tenofovir diphosphate. When present, the drug blocks DNA formation and the dye does
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
